Needham Rates Hinge Health (HNGE) buy, $76 Price Target

Needham reaffirms its buy rating for Hinge Health with a target price increase to $76, a 16.31% upside from the current price.

By EarningsIQ Research Desk · Published Jun 12, 2026, 9:14 PM EDT · Updated Jun 16, 2026, 9:02 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Needham rated Hinge Health, Inc. ($HNGE) "buy" with a $76 price target on June 11, 2026.

Since the rating, $HNGE is up 7.2% after 1 week, up 39.0% after 1 month and up 53.1% to date (from the $64.75 close on Jun 11, 2026).

HNGE Hinge Health, Inc.

$99.16 +117.65% year to date

Daily close · Oct 16, 2026

Key Points

On June 11, 2026, Needham reaffirmed its buy rating for Hinge Health, Inc. (NYSE: HNGE) with a new price target of $76.
Needham's $76 price target implies 16.31% upside from Hinge Health, Inc.'s ($HNGE) current $65.34 share price.
Hinge Health's shares are trading at $65.34, significantly below its 52-week high of $107.
The stock has a P/E ratio of 34.64, indicating growth potential in the healthcare technology sector.

Get $HNGE trade alerts by text

We text you when insiders, Congress or big funds trade $HNGE. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Hinge Health, Inc. alert may contain errors. Disclosures

Rating Reaffirmed with Increased Target

On June 11, 2026, Needham reiterated its buy rating for Hinge Health, Inc. (NYSE: HNGE) and raised the price target to $76. Analyst Ryan MacDonald noted this move reflects the firm's positive outlook on the company’s growth and prospects. The stock was trading at $65.34 at the time of the announcement, presenting a potential upside for investors.

Current Position and Analyst Opinions

The increase in Needham's target price indicates a shift in the firm's view on Hinge Health's future performance. The previous target was not disclosed, but the new target represents a strategic reassessment of the company's potential in the healthcare market.

Other Analysts on Hinge Health

Though there are no peers reported in this filing, Hinge Health has received predominantly positive coverage from analysts recently. Firms such as Keybanc and Barclays have also maintained their positive ratings on the stock, with price targets of $140 and $110, respectively. This generally favorable outlook suggests a consensus in the market regarding Hinge Health's growth in the health information services industry.

Stock Performance Context

Hinge Health's stock is currently priced at $65.34, which is well below its 52-week high of $107. The stock's performance has seen fluctuations, particularly following recent analyst reports and the current market sentiment about healthcare technology. This price level could provide a buying opportunity for investors looking for growth in this sector.

12-month forecast

$HNGE price target

Hinge Health, Inc. daily closes and this analyst's $76 target. Not advice.

Recent Earnings

Hinge Health reported revenue of approximately $720 million with a net margin of 15.1% for its latest fiscal year. The company has demonstrated strong revenue growth of 53% year-over-year, indicating robust demand for its services. Investors will be watching closely as the next earnings report is scheduled for November 2, 2026.

Insider Buying and Selling at Hinge Health, Inc.

Recent insider activity has shown that LLC Insight Holdings Group purchased a total of about 1.97 million shares on June 25 and June 29, 2026, reflecting confidence in the company's future. They sold 1.47 million shares on June 29, 2026, at an average price of $82.84, indicating they are still active in managing their position with Hinge Health.

What Hinge Health, Inc. Does

Hinge Health, Inc. focuses on automating and enhancing care delivery using technology to treat musculoskeletal issues. Through its innovative platform, the company provides AI-driven solutions for both acute and chronic pain management, primarily serving self-insured employers. This technological approach positions Hinge Health well in the growing healthcare technology market.

What's Ahead for Hinge Health, Inc.

Investors should keep an eye on the upcoming earnings report in November and watch for further updates from analysts as the healthcare technology landscape evolves. The reiteration of Needham's buy rating highlights the firm's confidence in Hinge Health's future, which may influence investor sentiment in the coming months.